Business Wire

Gemalto Advances Global IoT Connectivity with LPWA Module Platform Based on Latest Qualcomm LTE IoT Solution

Del

To meet booming global demand for Low Power Wide Area (LPWA) IoT connectivity, Gemalto announces a platform of innovative Cinterion IoT Modules based on the latest Qualcomm® 9205 LTE IoT modem from Qualcomm Technologies, Inc., a subsidiary of Qualcomm Incorporated. The new solution is designed to support global LTE-M and NB-IoT connectivity with optional 2G fallback from a single, ultra-small IoT module. Ready for the latest 3GPP specifications (Rel 14), the platform will be loaded with Gemalto security and value-added features specifically designed for compact, power-efficient IoT applications including smart meters, asset trackers, healthcare, wearable and smart city solutions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190107005501/en/

IoT LTE Module Credit: Gemalto

IoT LTE Module Credit: Gemalto

Global LPWA connectivity in a tiny package
Available in the second half of 2019, the first Cinterion products based on Qualcomm Technologies’ next-gen IoT LTE chipset will include the multimode Cinterion EXS62 IoT Module and Cinterion EXS82 IoT Module with 2G fallback. The miniaturized solutions are designed to deliver global connectivity and extended coverage range with support of power class 5. This can enable up to 70% reduced power consumption helping to preserve the battery for applications in remote locations. It can also reduce cost and complexity for device makers and ensures worldwide reliability, which is crucial for the 6 billion new IoT devices expected to leverage LPWAN connectivity by 20261.

Unique incremental FOTA for efficiency, longevity
The platform will leverage Gemalto’s innovative incremental FOTA technology with Lightweight M2M (LwM2M) to tackle the critical challenge of balancing bandwidth and power efficiency with software and security updates necessary over the long life of IoT devices. By streamlining overall firmware design and allowing precise revision of only the portion of code that needs updating, Gemalto can significantly reduce the overall update file size by 95% compared to competing LPWA modules. This will exceed benchmarks required by global mobile network operators and reduces transmission time, power draw and throughput. It’s essential for managing forthcoming 5G compliance updates and extending device lifespan as well as for allowing dynamic feature updates and customization.

eSIM and remote provisioning secures and simplifies connectivity
Built on Gemalto's expertise in securely managing billions of digital credentials, the new Cinterion platform will include an integrated onboard eSIM along with secure remote provisioning capabilities. Together, the solutions can authenticate IoT devices, encrypt data and securely manage connections to cellular networks globally. Embedded into the IoT module, tamper-resistant embedded SIMs will reduce the size and cost of solutions while simplifying the supply chain.

Steadfast security streamlines the device-to-cloud path
Embedding digital identity certificates inside Cinterion IoT Modules during manufacturing strengthens IoT device security and ensures data privacy. Leveraging a digital handshake authentication process, certificates verify the identity of device and applications to streamline enrollment in all the main IoT cloud platforms. It will also simplify development and reduces TCO for OEMs by eliminating the need to deploy their own secure production facilities.

“We are excited to work with strong industry leaders like Gemalto to expand the horizon of possibility in IoT solutions,” said Vieri Vanghi, vice president, product management, Qualcomm Europe, Inc. “Our collaboration with Gemalto on their new Cinterion LPWAN IoT Module Platform can allow OEMs to easily integrate and launch products using our cutting-edge Qualcomm 9205 LTE IoT modem, and in doing so, they will help enable massive IoT connectivity that can transform industries and make life better.”

“Gemalto’s Cinterion LPWAN IoT Module Platform will bring together our deep expertise in both IoT connectivity and digital security and provide a wealth of unique features that can allow device manufacturers to take the lead in IoT innovation,” said Andreas Haegele, SVP IoT Products, Gemalto. “Our continued collaboration with Qualcomm Technologies allows us to deliver on our customer promise of innovating new technologies to advance connectivity possibilities, support their business success and enable trust in the IoT.”

About Gemalto

Gemalto (Euronext NL0000400653 GTO) is the global leader in digital security, with 2017 annual revenues of €3 billion and customers in over 180 countries. We bring trust to an increasingly connected world.

From secure software to biometrics and encryption, our technologies and services enable businesses and governments to authenticate identities and protect data so they stay safe and enable services in personal devices, connected objects, the cloud and in between.

Gemalto’s solutions are at the heart of modern life, from payment to enterprise security and the internet of things. We authenticate people, transactions and objects, encrypt data and create value for software – enabling our clients to deliver secure digital services for billions of individuals and things.

Our 15,000 employees operate out of 114 offices, 40 personalization and data centers, and 35 research and software development centers located in 47 countries.

For more information visit www.gemalto.com, or follow @gemalto on Twitter.

Qualcomm is a trademark of Qualcomm Incorporated, registered in the United States and other countries.
The Qualcomm 9205 LTE modem is a product of Qualcomm Technologies, Inc. and/or its subsidiaries.

1 https://www.qualcomm.com/news/releases/2018/12/17/qualcomm-introduces-next-gen-cellular-chipset-purpose-built-iot

Contact information

Gemalto media contacts:
Tauri Cox
North America
+1 512 257 3916
tauri.cox@gemalto.com

Sophie Dombres
Europe Middle East & Africa
+33 4 42 36 57 38
sophie.dombres@gemalto.com

Piyush Prakash
Asia Pacific
+91 11 6623 1200
piyush.prakash@gemalto.com

Alexis Camarillo
Latin America
+52 5521223627
alexis.camarillo@gemalto.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Fishawack continues to build best-in-class service offering with Dudnyk acquisition20.3.2019 13:00:00 CETPressemelding

Fishawack, a leading independent healthcare communications specialist, is excited to announce its acquisition of Dudnyk, the Philadelphia-based healthcare communications agency. Dudnyk is an award-winning, full-service agency that specializes in creating insight-driven, authentic brand experiences that unite specialty physicians and their patients. They leverage strategic, scientific, and creative capabilities to serve clients in the biotech, pharmaceutical, and medical device industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190320005204/en/ Dudnyk leadership team includes Christopher Tobias, PhD, President; Laurie Bartolomeo, EVP, Creative Director; Drew Desjardins, EVP, Chief Strategy Officer; Annemarie Armstrong, EVP, Director of Client Services; John Kemble, EVP, Creative Producer. (Photo: Business Wire) Fishawack’s goal is to increase the range of healthcare communications services that it can offer to commerc

ExaGrid Nominated in Six Categories for the 2019 Network Computing Awards20.3.2019 12:00:00 CETPressemelding

ExaGrid ®, a leading provider of intelligent hyperconverged storage for backup, today announced that it has been nominated in six categories for the 2019 Network Computing Awards. ExaGrid has become a finalist for Data Centre Product of the Year, The Return on Investment Award, Hardware Product of the Year, Product of the Year, The Customer Service Award, and Company of the Year. Voting to determine the winner in each category is underway now and closes on April 23. The results will be revealed at an evening award ceremony in London on May 2. ExaGrid’s model EX63000E backup storage appliance with data deduplication is a nominee in four categories. The model provides the largest scale-out system and offers up to a 2PB full backup with an ingest rate of 432TB/hr, which is three times faster than any other backup storage on the market. “We are thrilled to be nominated by IT staff, and recognized by Network Computing, in six prestigious categories this year,” said Bill Andrews, CEO and Pre

Eos Biosciences Issued Patent for New Approach to Shuttle Therapeutics Across the Blood-Brain Barrier to Treat Brain Diseases20.3.2019 11:30:00 CETPressemelding

Eos Biosciences, Inc. (Eos), a nanomedicines company developing an efficient and versatile nanobiologic particle-based platform technology (Eosomes), announced that the U.S. Patent and Trademark Office has granted Eos Biosciences Patent No. 10,183,078, relating to a novel approach of using HER3-targeted Eosomes as a shuttle system for transporting various classes of therapeutics across the blood-brain barrier for treatment of brain disorders, including brain cancer. The patent is owned by Cedars-Sinai Medical Center and is exclusively licensed to Eos Biosciences. Details of the system will be highlighted in an upcoming manuscript from Lali Medina-Kauwe, PhD, Professor, Department of Biomedical Sciences, Cedars-Sinai. Omar Haffar, Ph.D., Founder, President and Chief Executive Officer, commented, “We’re very excited by the issuance of this pivotal patent and look forward to receiving similar approvals in other countries. This patent adds to Eos’ considerable IP portfolio covering the Eos

Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics20.3.2019 10:45:00 CETPressemelding

Vivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing gene therapy treatments for inherited liver disorders with high unmet medical need, and Pfizer Inc. (NYSE: PFE) announced today that Pfizer has acquired a 15% equity interest in Vivet and secured an exclusive option to acquire all outstanding shares. Pfizer and Vivet will collaborate on the development of VTX-801, Vivet’s proprietary treatment for Wilson disease. Wilson disease is a devastating, rare, chronic, and potentially life-threatening liver disorder of impaired copper transport that causes serious copper poisoning. In patients with Wilson disease, a monogenetic mutation disables the normal copper biliary excretion pathway leading to excess copper accumulation in the liver and other organs including the central nervous system. Untreated, Wilson disease results in various combinations and severity of hepatic (fibrosis and cirrhosis), neurologic and psychiatric symptoms, which can b

Fintech Company Rimilia Appoints Kevin Kimber as CEO20.3.2019 10:00:00 CETPressemelding

Rimilia, a fintech company helping finance departments simplify the complex, has appointed Kevin Kimber as CEO. The news follows another strong year for Rimilia. In 2018, Rimilia opened offices in Central London and Denver, Colorado in the U.S., and reported significant revenue growth on the previous year. Rimilia was founded in 2008 and its platform, created by finance professionals, uses RPA (robotic process automation) technology to help finance teams fast-track their cash flow by providing clearer information and better control. It has quickly become the industry leader, trusted by a number of global brands from HSBC to DHL and Santander, to provide visibility, improve efficiencies and guarantee cash flow. Rimilia works with any currency, any bank and in any language, and on average delivers 70% cost-savings and an 80% reduction in manual effort to its customers. Kevin joins Rimilia from Eight Roads Ventures (one of Rimilia’s investors), where he was a Venture Partner, advising its

Knopp Biosciences Enters Collaboration with Leading UK Investigators to Commence Phase 2 Clinical Trial of Dexpramipexole in Severe Eosinophilic Asthma20.3.2019 10:00:00 CETPressemelding

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases with high unmet need, today announced a collaboration with a consortium of leading medical researchers in the United Kingdom to evaluate the ability of Knopp’s lead drug candidate, dexpramipexole, to reduce exacerbations in people with severe eosinophilic asthma. The project is chiefly funded by the National Institute for Health Research (NIHR) and Medical Research Council (MRC) of the UK. The Chief Investigator for the Phase 2 multi-center, 52-week trial is Professor Salman Siddiqui, Professor of Airway Diseases at the University of Leicester and Consultant Respiratory Physician at Leicester’s Hospitals. Dexpramipexole is an orally available small molecule shown to selectively reduce eosinophil levels in multiple clinical trials, including in a Phase 2 study in hypereosinophilic syndrome (HES) and a Phase 2 trial in chr